Brief: Arovella Therapeutics Files IND Application With US FDA For First-In-Human Phase 1 Trial Of ALA-101
30/12/2025 01:20
Dec 30 (Reuters) - Arovella Therapeutics Ltd ALA.AX: FILES IND APPLICATION WITH U.S. FDA FOR FIRST-IN-HUMAN PHASE 1 TRIAL OF ALA-101 Further company coverage: ALA.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arovella Therapeutics
See all newsBrief: Arovella Therapeutics Appoints Acting CEO
Brief: Arovella Therapeutics Says Michael Baker Resigns As CEO
Brief: Arovella Therapeutics Says Elizabeth Stoner Will Be Retiring As Interim Chair
Brief: Arovella Therapeutics Says IND For Ala-101 Accepted By FDA
Brief: Arovella Therapeutics Appoints Lachie Mallia As CFO